Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neuromodulation of Mind-Wandering in Depression

NCT: NCT04832685 · ACTIVE_NOT_RECRUITING

NCT IDNCT04832685
StatusACTIVE_NOT_RECRUITING
Start Date2023-03-20
Completion2026-12

Brief Summary

The specific aim of this proposed study is to investigate the feasibility and therapeutic potential of LIFUP in changing negative cognition in depression. Specifically, the investigators will study if modulating DMN activity can change maladaptive mind-wandering. The investigators hypothesize that DOWN-modulation of the posterior cingulate cortex (PCC), a key DMN node, will decrease DMN resting state functional connectivity, perfusion, and activation during a cognitive-affective task (description below). The investigators also hypothesize that DOWN-modulation of the PCC will be associated with decreased mind-wandering and increased mindfulness. Finally, the investigators hypothesize that the opposite will be true for UP-modulation of the PCC.

Frequently Asked Questions

What is Neuromodulation of Mind-Wandering in Depression?

Neuromodulation of Mind-Wandering in Depression is a clinical trial registered under NCT04832685. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04832685?

The current status of NCT04832685 (Neuromodulation of Mind-Wandering in Depression) is: ACTIVE_NOT_RECRUITING.

When did Neuromodulation of Mind-Wandering in Depression start?

Neuromodulation of Mind-Wandering in Depression started on 2023-03-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.